These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 29947075)

  • 21. Cytokeratin 19 fragment is associated with severity and poor prognosis of interstitial lung disease in anti-MDA5 antibody-positive dermatomyositis.
    Gui X; Ma M; Ding J; Shi S; Xin X; Qiu X; Zhang Y; Qiu Y; Cao M; Huang M; Cao M; Dai J; Cai H; Xiao Y
    Rheumatology (Oxford); 2021 Aug; 60(8):3913-3922. PubMed ID: 33501503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum Krebs von den Lungen-6 concentrations reflect severity of anti-melanoma differentiation-associated protein 5 antibody positive dermatomyositis associated interstitial lung disease.
    Zhu Y; Wang L; Sun Y; Wang J; Lv C; You H; Xu L; Wang F; Zhang M; Tan W; Ke Y
    Clin Exp Rheumatol; 2022 Feb; 40(2):292-297. PubMed ID: 34874831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of long-term prognosis and relapse of dermatomyositis complicated with interstitial pneumonia according to autoantibodies: anti-aminoacyl tRNA synthetase antibodies versus anti-melanoma differentiation-associated gene 5 antibody.
    Isoda K; Kotani T; Takeuchi T; Kiboshi T; Hata K; Ishida T; Otani K; Kamimori T; Fujiwara H; Shoda T; Makino S
    Rheumatol Int; 2017 Aug; 37(8):1335-1340. PubMed ID: 28451794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Roles of biomarkers in anti-MDA5-positive dermatomyositis, associated interstitial lung disease, and rapidly progressive interstitial lung disease.
    Li X; Liu Y; Cheng L; Huang Y; Yan S; Li H; Zhan H; Li Y
    J Clin Lab Anal; 2022 Nov; 36(11):e24726. PubMed ID: 36221983
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis.
    Gono T; Kawaguchi Y; Satoh T; Kuwana M; Katsumata Y; Takagi K; Masuda I; Tochimoto A; Baba S; Okamoto Y; Ota Y; Yamanaka H
    Rheumatology (Oxford); 2010 Sep; 49(9):1713-9. PubMed ID: 20498012
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The comparison of nailfold videocapillaroscopy findings between anti-melanoma differentiation-associated gene 5 antibody and anti-aminoacyl tRNA synthetase antibody in patients with dermatomyositis complicated by interstitial lung disease.
    Wakura R; Matsuda S; Kotani T; Shoda T; Takeuchi T
    Sci Rep; 2020 Sep; 10(1):15692. PubMed ID: 32973255
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BATF2 balances the T cell-mediated immune response of CADM with an anti-MDA5 autoantibody.
    Li C; Liu M; Liu K; Li M; Liu Y; Li T; Wei Y; Long Y; He W; Shi X; Li Y; Zhang H
    Biochem Biophys Res Commun; 2021 Apr; 551():155-160. PubMed ID: 33740622
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antimelanoma Differentiation-associated Gene 5 Antibody: Expanding the Clinical Spectrum in North American Patients with Dermatomyositis.
    Moghadam-Kia S; Oddis CV; Sato S; Kuwana M; Aggarwal R
    J Rheumatol; 2017 Mar; 44(3):319-325. PubMed ID: 28089977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Type I interferon score is associated with the severity and poor prognosis in anti-MDA5 antibody-positive dermatomyositis patients.
    Qian J; Li R; Chen Z; Cao Z; Lu L; Fu Q
    Front Immunol; 2023; 14():1151695. PubMed ID: 37006269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis.
    Chen Z; Cao M; Plana MN; Liang J; Cai H; Kuwana M; Sun L
    Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1316-24. PubMed ID: 23908005
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined immunosuppressive therapy provides favorable prognosis and increased risk of cytomegalovirus reactivation in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis.
    Matsuda KM; Yoshizaki A; Kuzumi A; Fukasawa T; Ebata S; Yoshizaki-Ogawa A; Sato S
    J Dermatol; 2020 May; 47(5):483-489. PubMed ID: 32096271
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of Poor Outcome of Anti-MDA5-Associated Rapidly Progressive Interstitial Lung Disease in a Chinese Cohort with Dermatomyositis.
    Li Y; Li Y; Wu J; Miao M; Gao X; Cai W; Shao M; Zhang X; Xu Y; Cong L; He J; Sun X
    J Immunol Res; 2020; 2020():2024869. PubMed ID: 33299896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD.
    Horiike Y; Suzuki Y; Fujisawa T; Yasui H; Karayama M; Hozumi H; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Ogawa N; Suda T
    Rheumatology (Oxford); 2019 Dec; 58(12):2143-2152. PubMed ID: 31143953
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of usefulness in surfactant protein D as a predictor of mortality in myositis-associated interstitial lung disease.
    Kaieda S; Gono T; Masui K; Nishina N; Sato S; Kuwana M;
    PLoS One; 2020; 15(6):e0234523. PubMed ID: 32525903
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mitochondrial morphology and MAVS-IFN1 signaling pathway in muscles of anti-MDA5 dermatomyositis.
    Jiang Y; Liu Y; Zhao Y; Zheng Y; Yu M; Deng J; Hao H; Zhang W; Wang Z; Yuan Y
    Ann Clin Transl Neurol; 2021 Mar; 8(3):677-686. PubMed ID: 33576578
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Different Multivariable Risk Factors for Rapid Progressive Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis and Anti-Synthetase Syndrome.
    Zuo Y; Ye L; Chen F; Shen Y; Lu X; Wang G; Shu X
    Front Immunol; 2022; 13():845988. PubMed ID: 35320936
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of Serum Soluble CD163 with Polymyositis and Dermatomyositis, Especially in Anti-MDA5 Antibody-positive Cases.
    Kawasumi H; Katsumata Y; Nishino A; Hirahara S; Kawaguchi Y; Kuwana M; Yamanaka H
    J Rheumatol; 2018 Jul; 45(7):947-955. PubMed ID: 29657141
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease.
    Motegi SI; Sekiguchi A; Toki S; Kishi C; Endo Y; Yasuda M; Ikeuchi H; Sakairi T; Hara K; Yamaguchi K; Maeno T; Hiromura K; Ishikawa O
    Eur J Dermatol; 2019 Oct; 29(5):511-517. PubMed ID: 31617496
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Myositis-specific autoantibodies in dermatomyositis/polymyositis with interstitial lung disease.
    Li L; Wang H; Wang Q; Wu C; Liu C; Zhang Y; Cheng L; Zeng X; Zhang F; Li Y
    J Neurol Sci; 2019 Feb; 397():123-128. PubMed ID: 30616054
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical features of dermatomyositis associated with anti-MDA5 antibodies by age.
    Yamaguchi K; Yamaguchi A; Onuki Y; Itai M; Kashiwagi C; Takehara K; Aoki S; Kanaya A; Taguchi K; Umetsu K; Oshima K; Uchida M; Kimura H; Kasahara M; Takemura M; Hara K; Sekiguchi A; Motegi SI; Muro Y; Nakasatomi M; Motohashi R; Sakairi T; Nakagawa J; Hiromura K; Obokata M; Kurabayashi M; Maeno T
    Mod Rheumatol; 2021 Jan; 31(1):177-185. PubMed ID: 32149542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.